Pursuant to Regulations 30 and 33 of the SEBI (LODR) Regulations, 2015, we wish to inform that the Board of Directors, at its meeting held on Tuesday, 11th November, 2025, has inter alia ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.7 pts more than Nifty Microcap 250 and 8.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivanza Biosciences' Board approved unaudited standalone and consolidated financial results for Q2 FY26 (quarter ended September 30, 2025). Standalone revenue from operations jumped to Rs. 5,373.18 lakhs from Rs. 158.33 lakhs in Q2 FY25, while standalone profit before tax rose to Rs. 46.21 lakhs from Rs. 0.53 lakhs. Consolidated revenue for the quarter stood at Rs. 5,535.78 lakhs with PAT of Rs. 56.29 lakhs. The Board also approved a major diversification move by altering the main object clause of the MOA to include manufacturing and trading of plastic polymer films, plastic bags, paper bags, and flexible packaging materials, subject to shareholder approval via postal ballot (voting from Nov 17 to Dec 16, 2025). Additionally, CS Chaitra Arora was appointed as new Company Secretary & Compliance Officer, replacing CS Siddhi Shah who resigned effective September 26, 2025.
The sharp year-on-year revenue and profit growth signals a strong turnaround for the company, though the standalone operating cash flow remained negative (Rs. -56.20 lakhs for H1 FY26). The proposed diversification into packaging is a significant strategic pivot away from pure pharma and will require shareholder approval, which could reshape the company's business identity going forward.